Apellis Pharmaceuticals (APLS) and Sobi said Friday that new data from a phase 3 study showed that Empaveli demonstrated 68% proteinuria reduction that was sustained for one year.
The study evaluated Empaveli, or pegcetacoplan, in patients with kidney diseases C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis.
According to phase 3 data, patients treated with Empaveli also showed stabilization of kidney function as measured by estimated glomerular filtration rate, the companies said. The product candidate showed favorable safety and tolerability, with no new safety signals observed, the partners added.
Marketing applications for Empaveli are currently under review in Europe and the US, according to the statement.
Shares of Apellis were up more than 1% in recent trading Friday.
Price: 19.34, Change: +0.24, Percent Change: +1.26
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。